109 related articles for article (PubMed ID: 21725234)
1. Dose pattern and effectiveness of paliperidone extended-release tablets in patients with schizophrenia.
Lee JS; Ahn JH; Lee JI; Kim JH; Jung I; Lee CU; Lee JY; Lee SI; Kim CY
Clin Neuropharmacol; 2011; 34(5):186-90. PubMed ID: 21725234
[TBL] [Abstract][Full Text] [Related]
2. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
[TBL] [Abstract][Full Text] [Related]
3. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
Kramer M; Simpson G; Maciulis V; Kushner S; Vijapurkar U; Lim P; Eerdekens M
J Clin Psychopharmacol; 2007 Feb; 27(1):6-14. PubMed ID: 17224706
[TBL] [Abstract][Full Text] [Related]
4. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
Fowler JA; Bettinger TL; Argo TR
Clin Ther; 2008 Feb; 30(2):231-48. PubMed ID: 18343262
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.
Tzimos A; Samokhvalov V; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
Am J Geriatr Psychiatry; 2008 Jan; 16(1):31-43. PubMed ID: 18165460
[TBL] [Abstract][Full Text] [Related]
6. Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia.
Canuso CM; Bossie CA; Amatniek J; Turkoz I; Pandina G; Cornblatt B
Early Interv Psychiatry; 2010 Feb; 4(1):64-78. PubMed ID: 20199482
[TBL] [Abstract][Full Text] [Related]
7. Paliperidone extended-release for the treatment of schizophrenia.
Marino J; Caballero J
Pharmacotherapy; 2008 Oct; 28(10):1283-98. PubMed ID: 18823223
[TBL] [Abstract][Full Text] [Related]
8. Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone.
Canuso CM; Youssef EA; Bossie CA; Turkoz I; Schreiner A; Simpson GM
Int Clin Psychopharmacol; 2008 Jul; 23(4):209-15. PubMed ID: 18545059
[TBL] [Abstract][Full Text] [Related]
9. The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia.
Kim SW; Yoon JS; Kim YS; Ahn YM; Kim CE; Go HJ; Chee IS; Jung SW; Chung YC; Kim YD; Joe S; Lee J; Kwon YJ; Yoon BH; Jae YM
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):228-35. PubMed ID: 22516251
[TBL] [Abstract][Full Text] [Related]
10. [Treatment with paliperidone extended-release tablets in a case of resistant undifferentiated schizophrenia: clinical improvement with 12 mg and evaluation through 3TRE scale].
Rusconi AC; Carlone C; Muscillo M; Piccione M
Riv Psichiatr; 2009; 44(4):267-72. PubMed ID: 20066799
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.
Marder SR; Kramer M; Ford L; Eerdekens E; Lim P; Eerdekens M; Lowy A
Biol Psychiatry; 2007 Dec; 62(12):1363-70. PubMed ID: 17601495
[TBL] [Abstract][Full Text] [Related]
12. Changes in plasma concentrations of risperidone and 9-hydroxyrisperidone and the associated clinical effects during the switch from oral risperidone to extended-release paliperidone tablets in patients with schizophrenia.
Yang DS; Seong SJ; Yoon YR; Lim MS; Kwak KH; Lee SJ
J Psychopharmacol; 2014 Apr; 28(4):341-8. PubMed ID: 24346811
[TBL] [Abstract][Full Text] [Related]
13. Treatment of acute schizophrenia with paliperidone ER: predictors for treatment response and benzodiazepine use.
Heres S; Don L; Herceg M; Bidzan L; Blanc M; Siracusano A; Maciulis V; Lahaye M; Schreiner A
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():207-12. PubMed ID: 24096139
[TBL] [Abstract][Full Text] [Related]
14. Flexible dosing with paliperidone ER in the treatment of patients with acutely exacerbated schizophrenia: results from a single-arm, open-label study.
Schmauss M; Jukić V; Siracusano A; Bidzan L; Badescu GM; Maciulis V; Lahaye M; Hoeben D; Tessier C; Schreiner A
Curr Med Res Opin; 2012 Aug; 28(8):1395-404. PubMed ID: 22746355
[TBL] [Abstract][Full Text] [Related]
15. A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder.
Vieta E; Nuamah IF; Lim P; Yuen EC; Palumbo JM; Hough DW; Berwaerts J
Bipolar Disord; 2010 May; 12(3):230-43. PubMed ID: 20565430
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents.
Singh J; Robb A; Vijapurkar U; Nuamah I; Hough D
Biol Psychiatry; 2011 Dec; 70(12):1179-87. PubMed ID: 21831359
[TBL] [Abstract][Full Text] [Related]
17. Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release.
Pani L; Marchese G
Expert Opin Drug Deliv; 2009 Mar; 6(3):319-31. PubMed ID: 19317589
[TBL] [Abstract][Full Text] [Related]
18. Paliperidone: new drug. Just a metabolite of risperidone, a neuroleptic soon off-patent.
Prescrire Int; 2007 Dec; 16(92):236-7. PubMed ID: 18092400
[TBL] [Abstract][Full Text] [Related]
19. Hospitalization rates before and after initiation of paliperidone ER in patients with schizophrenia: results from open-label extensions of the US double-blind trials.
Janicak PG; Wu JH; Mao L
Curr Med Res Opin; 2008 Jun; 24(6):1807-15. PubMed ID: 18559166
[TBL] [Abstract][Full Text] [Related]
20. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.
Gopal S; Vijapurkar U; Lim P; Morozova M; Eerdekens M; Hough D
J Psychopharmacol; 2011 May; 25(5):685-97. PubMed ID: 20615933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
